The addition of plinabulin to docetaxel demonstrated durable anticancer benefit in terms of overall survival when used in the second- or third-line treatment of patients with EGFR wild-type non–small cell lung cancer who had progressed on a prior platinum-based regimen.
Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.
Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
VCN-01 was safe and elicited signs of antitumor activity in patients with intraocular retinoblastoma that was refractory to chemotherapy or radiotherapy.
